Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company whose news flow is closely tied to its acute care and oncology supportive care portfolio. The company regularly issues updates on its marketed products ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, as well as financial and corporate developments that affect HRTX stock.
On this page, readers can follow HRTX news related to quarterly and annual financial results, net revenue trends by product, and guidance updates disclosed in earnings press releases. Heron’s announcements often break out performance for its Acute Care franchise, which includes ZYNRELEF for postoperative pain and APONVIE for prevention of postoperative nausea and vomiting in adults, and its Oncology franchise, which includes CINVANTI and SUSTOL for prevention of chemotherapy-induced nausea and vomiting.
Company news also covers regulatory and clinical milestones for Heron’s products. Examples from past releases include FDA approvals and label expansions for ZYNRELEF in various soft tissue and orthopedic surgical procedures, and recognition of APONVIE in consensus guidelines for the management of postoperative nausea and vomiting. These items help investors and clinicians track how product indications and clinical positioning evolve over time.
In addition, Heron reports capital markets and governance events through press releases and corresponding SEC filings. Recent topics have included comprehensive capital restructuring, new credit facilities and convertible note transactions, adoption of a Tax Benefit Preservation Plan to protect net operating loss carryforwards, and Board-level changes such as cooperation agreements with investors and director appointments. For users monitoring HRTX, this news feed offers a consolidated view of operational, financial, regulatory, and governance developments that the company has publicly disclosed.
Heron Therapeutics reported Q3 2021 financial results, with net product sales of $23.2 million, a rise from $20.0 million in Q3 2020. The company achieved $65.7 million in net sales for the nine months ended September 30, 2021, compared to $68.0 million the prior year. ZYNRELEF, launched July 2021, generated $2.1 million in sales, with strong formulary approvals. Despite a net loss of $52.4 million for Q3 2021, down from $58.2 million in Q3 2020, cash reserves were $202.8 million as of September 30, 2021. Future guidance suggests moderated cash usage and potential sales growth in 2022.
Heron Therapeutics (Nasdaq: HRTX) will host a conference call on November 3, 2021, at 4:15 p.m. ET to discuss their third quarter 2021 financial results and recent business highlights. The call is accessible via phone for domestic and international callers and will also be available as a webcast on Heron's website. An archive will be provided for 60 days. Heron focuses on developing innovative treatments to meet unmet patient needs in acute care and oncology.
Heron Therapeutics, Inc. (Nasdaq: HRTX) submitted a supplemental New Drug Application (NDA) to the FDA for its product ZYNRELEF, expanding its indication to include foot and ankle, small-to-medium open abdominal, and lower extremity joint surgeries without the need for additional studies. This followed a successful Type C meeting with the FDA, which allows for two sequential NDA submissions. The company aims to significantly increase the number of indicated procedures, targeting up to 14 million surgeries. ZYNRELEF is the first extended-release local anesthetic approved for postoperative pain management.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that Barry Quart, CEO, and John Poyhonen, President, will engage in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. The event is scheduled for September 27, 2021, at 1:20 pm ET. A live webcast will be accessible via the company's website, with a replay available for 60 days post-event. Heron Therapeutics focuses on developing advanced treatments to meet significant unmet patient needs in acute care and oncology. For further details, visit www.herontx.com.
Heron Therapeutics (HRTX) reported financial results for Q2 and H1 2021, highlighting a net loss of $61 million and $113.6 million, respectively. Net product sales for oncology care amounted to $22.4 million in Q2, slightly down from $22.7 million a year prior. ZYNRELEF, a new product launched in July 2021, saw positive early adoption with 61 unique accounts placing orders. However, the company faces challenges in growth projections due to reduced cancer patient treatments amid the pandemic and increased competition. Cash reserves stand at $257.7 million, reflecting a strategic preparation for product launches.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced the publication of HOPE Hernia-1 study results for ZYNRELEF in hernia repair surgery. The study demonstrates over 90% of patients discharged without opioid prescriptions and 95% recovering opioid-free, showcasing ZYNRELEF's role in non-opioid multimodal analgesia. ZYNRELEF is an extended-release formulation of bupivacaine and meloxicam, approved for postsurgical analgesia. The findings emphasize ZYNRELEF’s potential to minimize opioid use, pivotal in addressing the opioid crisis.
Heron Therapeutics (HRTX) announced the online publication of a new analysis in the journal Pain Management, evaluating the effectiveness of ZYNRELEF (bupivacaine and meloxicam) in adults 65 years and older after bunionectomy and hernia repair. The analysis revealed that 58% of bunionectomy and 87% of hernia repair patients did not require opioids post-surgery. ZYNRELEF was well tolerated, showing a similar safety profile to bupivacaine, with no serious adverse events related to the medication. This positions ZYNRELEF as a significant improvement over standard opioid treatments.
Heron Therapeutics announced a contract with Apexus for ZYNRELEF under the 340B Drug Pricing Program, aimed at improving access to this FDA-approved medication for postoperative pain management. ZYNRELEF, a dual-acting local anesthetic, was approved on May 12, 2021, and provides pain relief for up to 72 hours, significantly reducing the need for opioids. This partnership seeks to ensure that discounted pricing is available to healthcare providers, helping to combat the opioid crisis. Over 90,000 opioid overdose deaths were reported in the year ending September 2020, underscoring the importance of ZYNRELEF's wide availability.
Heron Therapeutics, Inc. (Nasdaq: HRTX) has announced the commercial launch of ZYNRELEF, a dual-acting local anesthetic, now available through national wholesalers and specialty distributors in the U.S. Approved by the FDA on May 12, 2021, ZYNRELEF provides postoperative pain relief for up to 72 hours following surgeries like bunionectomy and total knee arthroplasty. The product aims to reduce opioid reliance and has shown significant efficacy in pain management. Heron has secured contracts with major purchasing organizations to enhance market penetration.
Heron Therapeutics (Nasdaq: HRTX) announced that CEO Barry Quart will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:00 AM PT. A live webcast of the event will be available on the company's website and will be archived for 60 days. Heron Therapeutics focuses on developing innovative treatments for unmet patient needs, especially in acute care and oncology.